542-32-5

Basic information

• Product Name: DL-2-AMINOADIPIC ACID
• Synonyms: 2-aminoadipate;2-aminoadipicacid;2-amino-hexanedioicaci;alpha-aminoadipicacid;(RS)-2-AMINOHEXANEDIOIC ACID;TIMTEC-BB SBB000133;DL-ALPHA-AMINOADIPIC ACID;DL-2-AMINOADIPIC ACID
• CAS NO: 542-32-5
• Molecular Formula: C₆H₁₁NO₄
• Molecular Weight: 161.16
• EINECS: 208-809-2
• Product Categories: Amino Acids & Derivatives;amino acids
• Mol File: 542-32-5.mol

Chemical Properties

• Melting Point: 196-198 °C(lit.)
• Boiling Point: 287.44°C (rough estimate)
• Flash Point: 173.9 °C
• Appearance: White to off-white/Powder or Crystalline Powder
• Density: 1.333
• Vapor Pressure: 2.74E-06mmHg at 25°C
• Refractive Index: 1.4230 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Aqueous Acid (Slightly)
• PKA: 2.14, 4.21, 9.77(at 25℃)
• Water Solubility: Soluble in water (2.2 mg/ml at 20°C), 1 M HCl (50 mg/ml), ethanol (slightly), ether (slightly), and 80% formic acid (25 mg/ml).
• Merck: 14,416
• BRN: 1773077
• CAS DataBase Reference: DL-2-AMINOADIPIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: DL-2-AMINOADIPIC ACID(542-32-5)
• EPA Substance Registry System: DL-2-AMINOADIPIC ACID(542-32-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-43
• Safety Statements: 22-24/25-36-26-36/37
• WGK Germany: 3
• RTECS: MO1852000
• Hazardous Substances Data: 542-32-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
DL-2-Aminoadipic Acid is used as a labeled amino acid for chemical research. Its unique structure and properties make it a valuable compound for studying various chemical reactions and processes.
Used in Pharmaceutical Industry:
DL-2-Aminoadipic Acid is used as a pharmaceutical intermediate. Its role in the formation of lysine, an essential amino acid for human health, makes it a crucial component in the development of various pharmaceutical products.
Used in Biotechnology:
As an amino acid isolated from Cholera vibrio, DL-2-Aminoadipic Acid can be utilized in biotechnological applications, such as the development of new drugs or therapies targeting specific diseases or conditions.

Biochem/physiol Actions

DL-2-Aminoadipic acid (AAA) is a six-carbon homolog of glutamate and a gliotoxic compound. It is generally used to considerably reduce the number of astroglia in cerebellar cultures that acts as a model to study the mechanisms of a-aminoadipic acid induced glial toxicity.

Purification Methods

Crystallise the acid from H2O. Alternatively purify it by precipitating the Cu salt and decomposing

InChI:InChI=1/C6H11NO4/c7-4(6(10)11)2-1-3-5(8)9/h4H,1-3,7H2,(H,8,9)(H,10,11)/p-1/t4-/m1/s1

Upstream product

• 3184-35-8 2-oxohexanedioic acid 
• 7209-06-5 2-chloro-adipic acid diethyl ester 
• 855912-39-9 2-(2,4-dinitro-phenylhydrazono)-adipic acid 
• 23291-02-3 2-phthalimido-adipic acid diethyl ester 
• 110440-57-8 (3-cyano-propyl)-phthalimido-malonic acid diethyl ester 
• 124-04-9 Adipic acid 
• 98484-48-1 6-oxo-piperidine-2-carboxylic acid amide 
• 101086-81-1 1,1,4-Tris-aethoxycarbonyl-1-acetamido-butan 
• 5680-61-5 diethyl 2-phthalimidomalonate 
• 5332-06-9 4-bromobutanenitrile 
• 24327-18-2 (+/-)-2-Azido-adipinsaeure 
• 6727-73-7 4-iodobutyronitrile 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 64-18-6 formic acid 

Downstream Products

• 70-26-8 2,5-diaminopentanoic acid 
• 56-87-1 L-lysine 
• 24325-19-7 (+/-)-2-benzyloxycarbonylamino-adipic acid diamide 
• 3770-22-7 D,L-2-ketopiperidine-6-carboxylic acid 
• 91958-56-4 (R,S)-N-benzoyl-2-aminoadipic acid 
• 17195-37-8 2-benzyloxycarbonylamino-adipic acid 
• 91952-75-9 (+/-)-2-Cyclohexyloxycarbonylamino-adipinsaeure 
• 80446-57-7 DL-α-aminoadipic acid γ-benzyl ester 
• 3269-62-3 2-bromohexanedioic acid,6-ethyl ester 
• 767590-77-2 (R,S)-N-phenylacetyl-2-aminoadipic acid 
• 256664-57-0 (R,S)-N-benzoyl-2-aminoadipic acid diethyl ester 
• 256664-58-1 (R,S)-N-phenylacetyl-2-aminoadipic acid diethyl ester 
• 256664-59-2 (R,S)-N-phenylpropionyl-2-aminoadipic acid diethyl ester 
• 112295-37-1 δ-benzyl N-(tert-butyloxycarbonyl)-DL-aminoadipate 

Relevant articles and documents

Preparation method of beta-homoglutamic acid

The invention belongs to the field of preparation of organic compounds, and provides a preparation method of beta-homoglutamic acid. The method is characterized in that: 3-cyclohexenecarboxylic acid is used as a raw material, beta-homoglutamic acid is synthesized at a high yield through three the steps of reactions of Curtius rearrangement, olefin oxidation and protection group removal, and beta-homoglutamic acid with high yield and high optical purity can be obtained through configuration retention by using optically pure 3-cyclohexenecarboxylic acid. The method has the advantages of easily available raw materials, mild reaction conditions and low cost, and is suitable for large-scale preparation of beta-homoglutamic acid.

METHOD FOR SYNTHESIS OF KETO ACID OR AMINO ACID BY HYDRATION OF ACETHYLENE COMPOUND

An object of the present invention is to provide a method for synthesis of keto acids by hydration of an acetylene compound (acetylene-carboxylic acids) under mild conditions free from harmful mercury catalysts and a method for synthesis of amino acids from acetylene-carboxylic acids in a single container (one-pot or tandem synthesis). In one embodiment of the method according to the present invention for synthesis of keto acids, acetylene-carboxylic acids is hydrated in the presence of a metal salt represented by General Formula (1), where M1 represents an element in Group VIII, IX, or X of the periodic table, and X1, X2, or X3 ligand represents halogen, H2O, or a solvent molecule, and k represents a valence of a cation species, and Y represents an anion species, and L represents a valence of the anion species, and each of K and L independently represents 1 or 2, and k × m = L × n.

Process for producing alpha 2,3/ alpha 2,8-sialyltransferase and sialic acid-containing complex sugar

The present invention can provide a process for producing a protein having α2,3/α2,8-sialyltransferase activity using a transformant comprising a DNA encoding a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a sialic acid-containing complex carbohydrate using a transformant capable of producing a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism.

Human CDR-grafted antibody and antibody fragment thereof

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Gene recombinant antibody and antibody fragment thereof

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Azapeptides useful in the treatment of Hepatitis C

The present invention relates to azapeptide compounds represented by the formula: pharmaceutical compositions containing such compounds, and the use thereof in the treatment of Hepatitis C viral infections.

Substituted quinoxaline-2-ones as glutamate receptor antagonists

A novel series of substituted quinoxaline 2-ones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

Peptides with an insulin-like action

Peptides with an insulin-like action, of formula I: STR1 in which G is a hydrogen atom, an amino add residue, or a monosubstituted or polysubstituted amino acid; D is an amino acid residue, a phosphoamino acid residue, a monosaccharide residue, or a covalent bond; E is --NH--(CH2)n --NR52, a glycerol residue, or --NH--(CH2)p --R6 --R7 ; R1 is (C1 -C4)-alkyl or =O; R2 is a sulfhydryl protecting group, (C1 -C3)-alkyl, or a hydrogen atom; R3 and R4, independently of one another, are a hydrogen atom or methyl; R5, each being identical or different, is a hydrogen atom, 1 to 6 monosaccharide residues, or 1 to 6 monosubstituted or polysubstituted monosaccharide residues; R6 is O PO4 H, PO2 H, NHCOO, S or OCOO; R7 is a hydrogen atom, 1 to 6 monosaccharide residues, or 1 to 6 monosubstituted or polysubstituted monosaccharide residues; w is an integer 1 or 2; their preparation and use for treatment of diabetes mellitus or insulin-independent diabetes.

Primordial Amino Acids by Reductive Amination of α-Oxo Acids in Conjunction with the Oxidative Formation of Pyrite

The theory of an autotrophic origin of life postulates a primordial formation of amino acids by a mild and specific chemical energy source, namely by the reductive amination of α-oxo acids in conjunction with the oxidative formation of pyrite.Here we show experimental proof for this reaction, which involves carbon dioxide as catalyst.

Asymmetric Catalysis by Vitamin B12: The Isomerization of Achiral Aziridines to Optically Active Allylic Amines

Achiral N-acylaziridines are isomerized to optically active N-acyl-allylamines in ee's of up to 95percent by catalytic amounts of cob(I)alamin in MeOH.